Market Overview

UPDATE: Morgan Stanley Downgrades Warner Chilcott to Underweight

Related WCRX
Actavis, Warner Chilcott Receive FTC Clearance for Actavis' Proposed Acquisition of Warner Chilcott
Top 4 Mid-Cap Stocks In The Drug Manufacturers-Other Industry With The Highest Profit Margin

Morgan Stanley reduced its rating on Warner Chilcott (NASDAQ: WCRX) from Equal-weight to Underweight.

Morgan Stanley commented, "We are downgrading WCRX from EW to UW; we see a more favorable risk-reward in other stocks. We question Warner's LT prospects since we est. 80% of 2013E revs are potentially threatened by generics, but future pipeline success and/or M&A could boost prospects."

Warner Chilcott closed at $17.20 on Monday.

Latest Ratings for WCRX

DateFirmActionFromTo
Jul 2013Leerink SwannUpgradesMarket PerformOutperform
Jun 2013JefferiesDowngradesBuyHold
May 2013Leerink SwannDowngradesOutperformMarket Perform

View More Analyst Ratings for WCRX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Downgrades Intraday Update Analyst Ratings

 

Related Articles (WCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters